Novo Nordisk to invest $2.3 billion in French facility to address GLP-1 drug shortage
.png)
Manufacturing for the diabetes and weight-loss drugs Ozempic and Wegovy is expected to increase with a billion-dollar investment Novo Nordisk production site located in Chartres, France.
Danish pharmaceutical giant Novo Nordisk announces a $2.3 billion investment into its Chartres, France manufacturing site to boost production of weight-loss and diabetes drugs such as Wegovy and Ozempic, among others.
A growing supply crisis of semaglutide drug products has European healthcare systems worried. The off-label use of Ozempic as an obesity treatment. Ozempic in particular has faced supply shortages in Europe because of its popularity in weight-loss treatment, while Wegovy is not yet widely available in Europe. Some nations are considering bans on off-label prescriptions for Ozempic; Germany has considered banning exports of the drug, while Belgium banned non-diabetes related prescriptions of Ozempic. Novo Nordisk itself has introduced rations for Ozempic starter kits in response to increased demand for weight-loss treatments. Earlier in November 2023, Novo Nordisk announced an increase in investment to $6 billion for production within Denmark.
Estimate analysis of the obesity drug market shows a potential worth of $100 billion by 2030. The investment into the French manufacturing plant will also serve as a boost for France’s economy as it faces a global economic slowdown. During the ‘Choose France’ summit earlier in the year, the office of French President Emmanuel Macron announced they had convinced Novo Nordisk CEO Lars Fruergaard Jorgensen to invest in the French manufacturing site. However, Novo Nordisk has yet to comment on this.
The investment will significantly increase the several types of manufacturing required for the production of GLP-1 drug class, with specialist operations for the filling of injection pens with the API semaglutide. Assembly and packaging operations of the injection pens will also be increased.
Source: Novo Nordisk invests $2.3 billion in France to boost obesity drug production [Accessed November 29, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-invests-23-mln-france-boost-output-2023-11-23/
Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance